Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy

Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy

Geographic atrophy, an eye disorder that starts as a loss of central vision and progressively worsens to total blindness, now has its first treatment. The FDA on Friday approved an Apellis Pharmaceuticals drug that slows the progression of this disease, which affects more than 1 million people in the U.S.
Approval of the Apellis drug, pegcetacoplan, covers all patients with geographic atrophy, a broad label that reflects the representative patient population tested in pivotal studies, Chief Medical Officer Caroline Baumal said during a Friday evening conference call. The Waltham, Massachusetts-based company plans to launch the drug in March, marketing the product under…

Continue Reading
HIMSSCast: Epic leaders on data-driven clinical trial innovation

HIMSSCast: Epic leaders on data-driven clinical trial innovation

The challenges of designing effective clinical trials, finding the right people to participate in them and building trial cohorts that are representative of the population at large, have been well-documented.With its recent Life Sciences initiative, Epic has set its sights on data-driven insights to improve the development of new therapeutics and interventions. That includes improving all parts of the clinical trial process – from how physicians educate their patients about potential cohorts, matching and connecting patients with promising research and helping make sure those studies are optimally beneficial for as many people as possible. Epic is already helping its provider customers…

Continue Reading
Automated Mass Spec Technique to Detect Antidepressants

Automated Mass Spec Technique to Detect Antidepressants

Scientists at Brown University have designed an automated liquid chromatography tandem mass spectrometry (LC-MS/MS) system that allows clinicians to rapidly and easily process patient samples to determine levels of antidepressant drugs in the body. Getting the correct dose of antidepressant drugs into the bloodstream is important to ensure efficacy and avoid side-effects. However, current assays to measure the levels of such drugs in the blood are cumbersome, require large blood samples, and involve multiple time-consuming steps, limiting their use by clinicians. This new system requires very small sample volumes, and employs a robot liquid handling system that is commonly found […]…

Continue Reading
AI can be a big help to healthcare workers, but there are legal issues to consider

AI can be a big help to healthcare workers, but there are legal issues to consider

As burnout among healthcare workers continues to be a major concern, the use of artificial intelligence, EHRs and other automation tools may be able to have a positive impact on hospitals and health systems.When it comes to artificial intelligence, some legal issues arise. That’s why we interviewed Carly Koza, an authority on this topic and Buchanan Ingersoll & Rooney associate. Buchanan Ingersoll & Rooney is a national law firm with 450 attorneys and government relations professionals across 15 offices representing companies including 50 of the Fortune 100.
Koza discusses what healthcare provider organizations should prepare for when it comes to growing AI…

Continue Reading
TBD Health Raises $4.4M Seed Round to Expand its Hybrid Sexual Healthcare Offerings Nationally

TBD Health Raises $4.4M Seed Round to Expand its Hybrid Sexual Healthcare Offerings Nationally

As Reproductive Rights are Defunded and Debated Nationally, TBD Health Aims to Democratize Access to Inclusive Sexual Care
TBD Health, a sexual healthcare provider revolutionizing the medical landscape through unparalleled digital and in-person clinical care, today announced a $4.4 million seed round led by Tusk Venture Partners, with participation from Springdale Ventures, Human Ventures, Expansion VC, Starbloom Capital, Hyphen Capital, and The Community Fund along with several strategic angels. With this new financing, TBD Health is expanding to all 50 states, democratizing access to its sexual healthcare offerings, consisting of at-home STD testing and emergency contraception available via telehealth or in-person in its Las…

Continue Reading
Blood Biotech Grifols Cuts Deep in the U.S. to Find €400M in Savings

Blood Biotech Grifols Cuts Deep in the U.S. to Find €400M in Savings

Grifols, a company that turns blood plasma into therapies for immunological disorders and other conditions, is laying off about 2,000 U.S. workers as part of a corporate restructuring projected to yield up to €400 million in annual cost savings, the biotech announced Wednesday.
The layoffs represent about 8% of the Barcelona-based company’s global workforce, but they will happen mainly in its U.S. plasma operations. That’s notable because as a company that relies on plasma, the U.S. is vital to its business. The starting point for Grifols’s therapies is blood plasma. Key to its drug-making process is fractionation, in which the protein components…

Continue Reading
Veradigm, Healthverity Uses Registry Data for Chronic Disease Research

Veradigm, Healthverity Uses Registry Data for Chronic Disease Research

February 14, 2023 – Health IT vendor Veradigm, formerly Allscripts, announced a collaboration with healthcare data ecosystem HealthVerity that will leverage registry data to advance chronic disease research. The partnership will bridge Veradigm’s cardiology and metabolic registries with consumer data collected by HealthVerity, offering clinical researchers access to research-ready data. The Veradigm Cardiology Registry boasts over 102 million patient records representing more than 19.9 million unique patients, making it one of the largest outpatient cardiovascular quality improvement registries. The registry follows cardiac patients over time, monitoring essential measures such as demographics, plan of care, cardiac events and comorbidities, exams, procedures, lab…

Continue Reading
Caraway, Ash Wellness Launch Partnership to Combat Rise in STIs on College Campuses

Caraway, Ash Wellness Launch Partnership to Combat Rise in STIs on College Campuses

In order to catch the attention of reporters, companies often look for creative news hooks to tie their announcements to. Two companies have decided to use Valentine’s Day to forward their message of sexually transmitted infection prevention. How romantic!
Digital health startup Caraway Health is teaming up with at-home testing company Ash Wellness to provide STI kits for those aged 18 to 27, the companies announced Tuesday. New York City-based Caraway provides mental, physical and reproductive health services for Gen-Z populations, with a particular focus on women and people assigned female at birth. It offers an app that enables users to access its…

Continue Reading